Hutchison China MediTech Limited ("Chi-Med") is a China-based globally-focused healthcare group which researches, develops, manufactures and sells pharmaceuticals and health-related consumer products.

Its Innovation Platform focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets and distributes prescription drugs and consumer health products in China.

Chi-Med is listed on the London Stock Exchange’s AIM market (AIM: HCM). It is majority owned by CK Hutchison Holdings Limited (SEHK: 0001), a leading international conglomerate committed to innovation and technology with over a quarter of a million employees in more than 50 countries and annual sales of over US$50 billion.

http://www.chi-med.com/eng/global/home.php

Interim Results

RNS


RNS Number : 5395N

Hutchison China Meditech Limited

29 July 2014












Hutchison China MediTech Limited ("Chi-Med")

(AIM: HCM)



Interim Results for the Six Months Ended 30 June 2014



China Healthcare Division profit up 20%. Drug R&D Division progressing 10 clinical trials.

Strong outlook.





London: Tuesday, 29 July 2014: Chi-Med, the China-based healthcare and consumer products group, today announces its unaudited financial results for the six months ended 30 June 2014.

Chi-Med Group results are reported under International Financial Reporting Standard, IFRS 11 "Joint Arrangements" ("IFRS11"), which requires the equity accounting principle for the reporting of joint ventures ("JVs") which means that the income statements and statements of financial position of JVs are not proportionately consolidated as they have been in the past. However, total revenues of the JVs will continue to be disclosed on a voluntary basis under the divisional summaries below.

Results are reported in US dollar currency unless otherwise stated.



Group Results

· Revenue, under IFRS11, on continuing operations up 73% to $30.3 million (H1 2013: $17.6m).

· Net profit attributable to Chi-Med equity holdersup 97% to$6.4 million (H1 2013: $3.3m).

· Stable cash position: cash and cash equivalents at the Chi-Med Group level of $59.4 million (31 December2013: $46.9m); in addition, and not included at Chi-Med Group level, cash and cash equivalents held at the JV level of $91.6 million (31 December 2013: $99.0m).



China Healthcare Division

· Total sales of subsidiaries and JVs up 15% to $261.7 million (H1 2013: $227.5m).

· Net profit attributable to Chi-Med equity holders up 20% to $17.3 million (H1 2013: $14.4m).

· Commercial restructure complete - Good Supply Practice ("GSP") distribution companies now in place to enable the 2,700-person commercial team to sell third party/related party products.

· China low-price drug policy and key raw material price declines providing profitability tailwind.



Drug R&D Division

· Revenue of $9.9 million (H1 2013: $10.5m) from an AZD6094 (HMPL-504/volitinib) development milestone and service income from Nutrition Science Partners Limited ("NSP") and Janssen Pharmaceuticals Inc. (part of the Johnson & Johnson group of companies) ("Janssen").

· Net loss attributable to Chi-Med equity holders up 31% to $6.3 million (H1 2013: -$4.8m) due to continuing NSP investment in HMPL-004 global Phase III registration trials.

· 10 clinical trials progressing rapidly and building value. 2 Phase III registration studies on HMPL-004 in ulcerative colitis (NATRUL-3 and NATRUL-4); 3 Phase II proof-of-concept studies (AZD6094 in papillary renal cell carcinoma and fruquintinib in third-line colorectal and non-small cell lung cancer); 3 Phase Ib expansion studies (AZD6094 non-small cell lung cancer, sulfatinib in neuroendocrine tumours, and epitinib in non-small cell lung cancer with brain metastasis); and 2 Phase I studies (HMPL-523/Syk inhibitor for inflammation and theliatinib in solid tumours).

· Spending of $19.8 million (H1 2013: $15.2m) on clinical trials balanced by aggregate $20.1 million (H1 2013: $38.1m) cash and equity injections and contractual obligations from partners received by Drug R&D Division subsidiaries and JVs.



Consumer Products Division

· Sales from continuing operations up 16% to $6.4 million (H1 2013: $5.5m) from expansion of the broad organic and natural product line of Hutchison Hain Organic Holdings Limited ("Hutchison Hain Organic").

· Breakeven net profit on continuing operations attributable to Chi-Med equity holders of $0.0 million (H1 2013: -$0.4m).



Christian Hogg, CEO of Chi-Med, said:

"Chi-Med has significantly increased its net profit at a time when it is managing 10 clinical trial programmes and maintaining a deep and active discovery research programme, which together is adding substantial shareholder value. This is an achievement which is testimony to the balance of our businesses, our common sense approach to financing and our strategy of collaboration with powerful industry partners to help accelerate and enhance our own programmes.

We expect to continue adding significant shareholder value in the second half and beyond."

Hutchison China Meditech: Panmure Gordon raises target price from 950p to 1200p keeping a buy recommendation.

Hutchison China MediTech: UBS raises target price from 1000p to 1250p keeping a buy recommendation.

MIDAS SHARE TIPS: Chinese drugs firm MediTech looks healthy after doubling in three years

By Joanne Hart, Financial Mail On Sunday

Published: 22:18, 9 August 2014 | Updated: 22:18, 9 August 2014

The Chinese spend an average £160 per head a year on healthcare compared with more than £5,000 in the US.

The figure is so low because for decades Chinese communism did not involve state healthcare. If people fell ill, they paid for treatment or went without.


However, government spending on healthcare rose tenfold from 2005 to 2013, hitting £80billion last year and further expansion is scheduled for years to come.


Good prognosis: Chinese spending on healthcare is rising



Fast-growing drugs firm Hutchison China MediTech is well-positioned to reap the benefits. Midas recommended the shares in May 2011, when they were 447½p.


After struggling during that year, they have progressed in leaps and bounds and are now trading at 1032½p.

City brokers believe they have further to run, but investors who have more than doubled their money in the past three years may be wondering if they should hedge their bets and sell some stock now.


Founded in 2000, Hutchison China MediTech was set up as a subsidiary of the giant Hong Kong conglomerate Hutchison Whampoa. Focused on developing, manufacturing and selling drugs and wellbeing products in China, the business, known as Chi-Med, listed on Aim in 2006.


The group has grown fast since then, running three main divisions: a consumer products arm selling wellbeing items such as organic tea and healthy snacks; a healthcare arm selling prescription and overthe- counter drugs; and a research and development arm working on new drugs.

It is this last division which is expected to deliver the most exciting growth over the next few years. The firm has set up joint ventures with international players such as AstraZeneca, Johnson & Johnson and Lilly, and is in advanced trials on a number of cancer treatments.

Chi-Med is also working with Nestle on a drug based on traditional Chinese herbal remedies for Crohn’s disease and related conditions.


News on the latest trial of this product is expected later this month and could trigger further investment by Nestle if results are good or a winding down of the trial if results are poor.

The healthcare business used to focus on traditional Chinese medicine – still the first option for many Chinese. Increasingly, however, consumers take conventional drugs alongside herbal remedies, so Chi-Med has broadened its offer.


The group sells more than 200 drugs, mainly for colds, flu and heart disease, and runs a sales force of more than 2,500 across 600 Chinese cities.


Until recently, Chi-Med sold only its own products, including two household brands, but it now sells other manufacturers’ drugs too, which should boost profits.

The consumer business has been slow to take off, as many Chinese are as yet uninterested in designer teas and upmarket organic crisps. Looking further ahead however, this subsidiary has serious potential. In the first six months of this year, group profits after tax doubled to $6.4million (£3.8million) compared with the same period last year.


Analysts forecast a 45 per cent increase in full-year figures to $17.5million, rising to $25million next year.


Midas verdict: Chi-Med has made good progress and should continue to deliver. Investors who bought in 2011 should hedge their bets and sell 50 to 60 per cent of their stock. New investors should buy on any short-term weakness.


Traded on: Aim


Ticker: HCM

HMPL-004 Interim Analysis

RNS


RNS Number : 9920O

Hutchison China Meditech Limited

13 August 2014






Hutchison China MediTech Limited ("Chi-Med")

(AIM: HCM)



HMPL-004 NATRUL-3 interim analysis result



London: Wednesday, 13 August 2014: Nutrition Science Partners Limited ("NSP"), a 50/50 joint venture between Chi-Med and Nestlé Health Science SA, today announces that a planned interim analysis was conducted on NATRUL-3, the global Phase III induction trial of HMPL-004 vs. placebo in ulcerative colitis. An independent Data Safety and Monitoring Committee ("DSMC") evaluated the unblinded data of two doses of HMPL-004 vs. placebo, and has recommended that NSP terminate the study. No meaningful safety signals or risks for patients were identified, and further analysis and review of the data will be conducted. The NSP Board will continue to evaluate the potential opportunities of HMPL-004 in new indication areas and alternative regulatory pathways.

Patient enrolment in Phase II study completed

RNS


RNS Number : 6607P

Hutchison China Meditech Limited

21 August 2014












Hutchison China MediTech Limited ("Chi-Med")
(AIM: HCM)



Patient enrolment completed ahead of schedule for fruquintinib's Phase II study in colorectal cancer



London: Thursday, 21 August 2014: Chi-Med, today announces that Hutchison MediPharma Limited ("HMP"), its majority owned drug R&D company, has completed patient enrolment in a Phase II clinical trial of fruquintinib (HMPL-013) in colorectal cancer ("CRC") in China. The proof-of-concept study is investigating the efficacy and safety of fruquintinib, HMP's investigational small molecule inhibitor of vascular endothelial growth factor receptors ("VEGFR").



This randomised, double-blind, placebo-controlled, multi-centre, proof-of-concept Phase II study is targeted at treating patients with metastatic CRC, who have failed at least two prior chemotherapies, including fluoropyrimidine, oxaliplatin and irinotecan. A total of 71 patients have now been randomised to receive fruquintinib plus best supportive care ("BSC") or placebo plus BSC at a 2:1 ratio. The primary endpoint is progression free survival, with secondary endpoints including disease control rate, overall response rate, overall survival and safety. As a result of the rapid patient enrolment, data from this trial is expected in early 2015.



Fruquintinib is designed to selectively inhibit VEGF receptors, namely VEGFR1, VEGFR2, and VEGFR3. In the first-in-human Phase I clinical trial 40 patients were treated with fruquintinib. Detailed results of the Phase I clinical trial are available at http://chi-med.com/eng/irinfo/presentations.htm, and were presented at the annual meeting of the American Association for Cancer Research in April 2013. Based on the Phase I data in CRC, a Phase Ib study was initiated which treated a further 62 CRC patients. Detailed results of the Phase Ib clinical trial were presented at the annual meeting of the American Society of Clinical Oncology in May 2014, and also can be found at http://chi-med.com/eng/irinfo/presentations.htm.



In October 2013, HMP entered into a licensing, co-development and commercialisation agreement in China with Eli Lilly and Company for fruquintinib.





Ends

Co-promotion agreement with Merck Serono

RNS


RNS Number : 0157T

Hutchison China Meditech Limited

01 October 2014








Hutchison China MediTech Limited ("Chi-Med")

(AIM: HCM)



Press Release

Chi-Med and Merck Serono sign co-promotion agreement



London: Wednesday, 1 October 2014: Chi-Med, the pharmaceutical and healthcare company based primarily in China, today announces that Chi-Med, through its subsidiary Hutchison Whampoa Sinopharm Pharmaceuticals (Shanghai) Company Limited ("Hutchison Sinopharm"), has signed a co-promotion agreement with Merck Serono Co., Ltd. ("Merck Serono") a subsidiary of Merck in China to market certain cardiovascular prescription drug products in China.



Hutchison Sinopharm will exclusively co-promote Merck Serono's Bisoprolol Fumarate tablets, under the Concor® trademark, in several provinces in China. Concor® is a major brand in the beta-blocker sub-segment of the cardiovascular prescription drug market in China.



Chi-Med today operates a commercial network in China of approximately 1,600 cardiovascular market focused medical sales representatives, covering more than 13,000 hospitals, through its joint ventures, Shanghai Hutchison Pharmaceuticals Limited and Hutchison Sinopharm.

Ends

Enquiries

Signal Update

Our system’s recommendation today is to BUY. The BULLISH STOP LOSS pattern finally received a confirmation because the prices crossed above the Stop Loss level which was at 1,229.4000, and our valid average buying price stands now at 1,246.5000. The previous SELL signal was issued on 10/11/2014, 2 days ago, when the stock price was 1,198.7500. Since then HCM.L has risen by +3.98%.

Market Outlook

A rally after a bear setup can occasionally turn into an explosive long trade. We may be on the verge of catching one of them. There is now a strong positive sentiment in the market despite the absence of a bullish pattern. The bullish stop loss is finally confirmed and a BUY signal is generated. Market wants to reward the bulls. It may be now the right time to be part of this boost and bullish market sentiment by joining the growing bullish crowd.



http://www.britishbulls.com/SignalPage.aspx?lang=en&Ticker=HCM.L

Signal Update

Our system’s recommendation today is to STAY LONG. The previous BUY signal was issued on 12/11/2014, 6 days ago, when the stock price was 1,246.5000. Since then HCM.L has risen by +6.70%.

Market Outlook

The bulls are in full control. The negative sentiment that led to the last bearish pattern has evaporated. Besides, the signal is suggesting to STAY LONG. It is best to follow the signal and continue to hold this security


http://www.britishbulls.com/SignalPage.aspx?lang=en&Ticker=HCM.L

Hutchison China Meditech: Panmure Gordon raises target price from 1200p to 1500p and keeps a 'buy' recommendation.

Director's Shareholding

RNS


RNS Number : 5784X

Hutchison China Meditech Limited

20 November 2014












Hutchison China MediTech Limited ("Chi-Med")

(AIM: HCM)





Director's Shareholding





London: Thursday, 20 November 2014: Chi-Med received notification on 20 November 2014 that Mr Simon To, Executive Chairman and Director of Chi-Med, purchased 41,000 ordinary shares of US$1.00 each in Chi-Med (the "Shares") at a price of GBP13.50 per share on 18 November 2014.



Following this purchase, Mr To is beneficially interested in 41,000 Shares, representing approximately 0.08% of the current issued share capital of Chi-Med.

Hutchison China MediTech: UBS raises target price from 1200p to 1590p and reiterates a 'buy' recommendation.

Initiation of fruquintinib Phase III study

RNS


RNS Number : 7343Z

Hutchison China Meditech Limited

15 December 2014






Hutchison China MediTech Limited ("Chi-Med")

(AIM: HCM)



Initiation of fruquintinib Phase III registration study in colorectal cancer



London: Monday, 15 December 2014: Chi-Med today announces that Hutchison MediPharma Limited ("HMP"), its majority owned R&D company, has initiated FRESCO, a Phase III registration study in colorectal cancer ("CRC") patients in China, for fruquintinib (HMPL-013), its investigational small molecule which selectively inhibits vascular endothelial growth factor receptors ("VEGFR"). Preparations and site selection began in the middle of this year, with the first patient dosed on 12 December 2014.



This randomised, double-blind, placebo-controlled, multicentre, Phase III registration study is targeted at treating patients with locally advanced or metastatic CRC, who have failed at least two prior systemic antineoplastic therapies, including fluoropyrimidine, oxaliplatin and irinotecan. Patients will be randomised at a 2:1 ratio to receive either: 5 milligrams of fruquintinib orally once per day, on a three-weeks-on / one-week-off cycle, plus best supportive care ("BSC"); or placebo plus BSC. The primary endpoint is overall survival, with secondary endpoints including progression free survival, objective response rate, disease control rate and duration of response. More than 400 patients will be enrolled in about 25 centres, with top-line results expected in 2016.



Fruquintinib is designed to selectively inhibit VEGF receptors, namely VEGFR1, VEGFR2, and VEGFR3. In the first-in-human Phase I clinical trial 40 patients were treated with fruquintinib. Detailed results of the Phase I clinical trial are available at http://chi-med.com/eng/irinfo/presentations.htm, and were presented at the annual meeting of the American Association for Cancer Research in April 2013. Based on the Phase I data in CRC, a Phase Ib study was initiated which treated a further 62 CRC patients. Detailed results of the Phase Ib clinical trial were presented at the annual meeting of the American Society of Clinical Oncology in May 2014, and also can be found at http://chi-med.com/eng/irinfo/presentations.htm. Clinical trials for solid tumours including CRC, non-small cell lung cancer and gastric cancer are ongoing at various stages in China as either single-agent therapy or combined with chemotherapy.



In October 2013, HMP entered into a licensing, co-development and commercialisation agreement in China with Eli Lilly and Company for fruquintinib.



Ends
---------------------------------------------------------------------------------------------
15 Dec Panmure Gordon 1,500.00 Buy

Notice of Results
RNS
RNS Number : 9946C
Hutchison China Meditech Limited
26 January 2015









Hutchison China MediTech Limited ("Chi-Med")

(AIM: HCM)





Notice of Announcement of 2014 Final Results





London: Monday, 26 January 2015: Chi-Med will be announcing its final results for the year ended 31 December 2014 on Thursday, 26 February 2015. An analyst presentation will be held at 9:00 am on the same day at Citigate Dewe Rogerson, 3 London Wall Buildings, London, EC2M 5SY.

Distribution Agreement for Seroquel in China
RNS
RNS Number : 4649D
Hutchison China Meditech Limited
29 January 2015







Hutchison China MediTech Limited ("Chi-Med")

(AIM: HCM)



Press Release

Hutchison Sinopharm and AstraZeneca China

signed an exclusive distribution agreement on Seroquel® in China



London: Thursday, 29 January 2015: Chi-Med, the pharmaceutical and healthcare company based primarily in China, today announces thatHutchison Whampoa Sinopharm Pharmaceuticals (Shanghai) Company Limited ("Hutchison Sinopharm"), a subsidiary of Chi-Med, has entered intoan exclusive distributionagreement with AstraZeneca (Wuxi) Trading Co., Ltd. ("AstraZeneca"), a subsidiary of AstraZeneca PLC, to distribute and market in China the product Seroquel®, an antipsychotic prescription drug owned by AstraZeneca PLC.



Hutchison Sinopharm will be the exclusive first-tier distributor todistribute and marketAstraZeneca's Quetiapine Tablets, under the Seroquel® trademarkin China. Seroquel® is a first-line antipsychotic medicine for the treatment of schizophrenia and bipolar disorder, which was launched in China in 2001. The compound annual growth rate of the antipsychotic prescription drug market in China was approximately 21%from 2009 to 2013 driven by increasing awareness, diagnosis and treatment of central nervous system related diseases in China.



Hutchison Sinopharm, established in April 2014, provides marketing and commercialisation services to pharmaceutical companies in China. Chi-Med, through Hutchison Sinopharm as well as Shanghai Hutchison Pharmaceuticals Limited, currently operates a commercial network in China of over 1,600 medical sales representatives covering more than 13,000 hospitals.



Christian Hogg, Chi-Med CEO said: "This exciting collaboration with AstraZeneca, a most important strategic partner for Chi-Med, will allow us to leverage our considerable commercial presence in China against a highly attractive and fast growing commercial opportunity. Seroquel® is a very strong global brand and we look forward to helping to grow its distribution and business in China."





Ends

29 Jan Panmure Gordon 1,600.00 Buy

Final Results


Consolidated Group Results (IFRS11)

· Revenue up 100% to $91.8 million (2013: $46.0m).

· Net profit attributable to Chi-Med equity holders of $5.4 million (2013: $5.9m) as the Company continues to balance a dramatic increase in clinical trial activity on seven new drug candidates with rapidly increasing profit in the China Healthcare Division.

· Cash positive overall during 2014 with Group level cash and bank balances of $51.1 million (31 December 2013: $46.9m). In addition, cash and bank balances held at the joint venture ("JV") level $77.0 million (31 December 2013: $99.0m) which is being used to fund construction of two new large-scale factories.

26 Feb Panmure Gordon 1,600.00 Buy

Patient enrolment completion for Phase II study
RNS
RNS Number : 7433G
Hutchison China Meditech Limited
06 March 2015







Hutchison China MediTech Limited ("Chi-Med")

(AIM: HCM)





Patient enrolment completion for fruquintinib's Phase II study in non-small cell lung cancer. Fruquintinib development moving rapidly in four parallel studies in non-small cell lung cancer, colorectal cancer and gastric cancer.



London: Friday, 6 March 2015: Chi-Med, today announces that Hutchison MediPharma Limited ("HMP"), its majority owned drug R&D company, has completed patient enrolment in a Phase II clinical trial of fruquintinib (HMPL-013) in non-small cell lung cancer ("NSCLC") patients in China. The proof-of-concept ("POC") study is investigating the efficacy and safety of fruquintinib, HMP's investigational small molecule inhibitor of vascular endothelial growth factor receptors ("VEGFR").



This randomised, double-blind, placebo-controlled, multi-centre, POC Phase II study is targeted at treating non-squamous NSCLC patients who have failed second-line standard chemotherapy. A total of 91 patients have now been randomised to receive fruquintinib plus best supportive care ("BSC") or placebo plus BSC at a 2:1 ratio. The primary endpoint is progression free survival, with secondary endpoints including disease control rate, overall response rate, overall survival and safety. As a result of the rapid patient enrolment, data from this trial is expected in mid of 2015.



Fruquintinib is designed to selectively inhibit VEGF receptors, namely VEGFR1, VEGFR2, and VEGFR3. In the first-in-human Phase I clinical trial 40 patients were treated with fruquintinib. Detailed results of the Phase I clinical trial are available at http://chi-med.com/eng/irinfo/presentations.htm, and were presented at the annual meeting of the American Association for Cancer Research in April 2013.



Based on the Phase I data in colorectal cancer ("CRC"), a Phase Ib study was initiated which treated a further 62 CRC patients. Detailed results of the Phase Ib clinical trial were presented at the annual meeting of the American Society of Clinical Oncology in May 2014, and also can be found at http://chi-med.com/eng/irinfo/presentations.htm.



In April 2014, HMP initiated the first POC Phase II study, which was a randomised, double-blind, placebo-controlled, multi-centre Phase II clinical trial targeted at patients with metastatic CRC. The POC Phase II study subsequently completed enrolment in August 2014, and will report data during the first half of 2015.



In October 2014, HMP initiated a Phase Ib dose-finding study of fruquintinib, in combination with paclitaxel, in second line gastric cancer patients.



In December 2014, HMP initiated FRESCO, a Phase III registration study in patients with locally advanced or metastatic CRC, who have failed at least two prior systemic antineoplastic therapies, including flouropyrimidine, oxaliplatin and irinotecan. FRESCO will enrol more than 400 patients in 25 centres in China, with top-line results expected in 2016.



In October 2013, HMP entered into a licensing, co-development and commercialisation agreement in China with Eli Lilly and Company for fruquintinib.





Ends

Trial of fruquintinib achieves primary endpoint
RNS
RNS Number : 7809I
Hutchison China Meditech Limited
30 March 2015







Hutchison China MediTech Limited ("Chi-Med")

(AIM: HCM)





The first proof-of-concept trial of fruquintinib achieves primary efficacy endpoint



London: Monday, 30 March 2015: Chi-Med, today announces that Hutchison MediPharma Limited ("HMP"), its majority owned drug R&D company, successfully achieved the primary endpoint in the first proof-of-concept ("POC") trial of fruquintinib in patients with metastatic colorectal cancer ("mCRC") in China. The top-line results demonstrated that the trial clearly succeeded in meeting the primary efficacy endpoint of progression free survival.



Assessment of secondary efficacy endpoints, including objective response rate, disease control rate, and overall survival is ongoing, with all appearing in-line with expectations at the February 2015 six-month data cut-off. The adverse events demonstrated in this POC study are consistent with the known safety profile for fruquintinib without major unexpected safety issues. Full detailed results from this trial will be disclosed in due course.



This is the first POC Phase II study for fruquintinib aimed at comparing the efficacy and safety of fruquintinib plus best supportive care ("BSC") versus placebo plus BSC in patients with mCRC as a third-line or above therapy. It is a randomised, double-blind, placebo-controlled, multi-centre, POC Phase II study to treat mCRC patients who have failed at least two prior chemotherapies, including fluoropyrimidine, oxaliplatin and irinotecan. A total of 71 patients were randomised to receive fruquintinib plus BSC or placebo plus BSC at a 2:1 ratio. The trial was initiated in April 2014 and completed patient enrolment in August 2014.



30 Mar Panmure Gordon 1,650.00 Buy